Fig. 10: Gαi3 KO impedes pancreatic cancer cell growth in vivo.
From: Identification of Gαi3 as a promising molecular oncotarget of pancreatic cancer
priPC-1 cells with the Gαi3 sgRNA1-expressing lenti-CRISPR/Cas9-KO construct (“ko-Gαi3-s1”) or the lenti-CRISPR/Cas9-KO construct (“Cas9-C”) were s.c. injected to flanks of the nude mice at a concentration of 20 million cells per mouse, with six mice included in each experimental group. The volumes of the priPC-1 xenografts (A) and the mice body weights (D) were monitored and recorded at five-day intervals. The daily growth rate of the priPC-1 xenografts was also assessed (B). Thirty days post-injection, the developed xenografts were surgically removed and tumor weights were recorded (C). Analysis of protein expression was conducted on tissue lysates derived from the harvested priPC-1 xenografts (E–G). The data were presented as mean ± standard deviation (SD, n = 6). *P < 0.05 versus “Cas9-C” group. “N. S.” stands for P > 0.05.
